

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5309621

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JUDITH CAMPBELL	11/27/2017
KENNETH KARANJA	11/27/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CALIFORNIA INSTITUTE OF TECHNOLOGY
<b>Street Address:</b>	1200 E. CALIFORNIA BLVD.,
<b>City:</b>	PASADENA
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	91125
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16206611
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-542-6000
<b>Email:</b>	cdipasupil@mintz.com, ipdocketingBOS@mintz.com
<b>Correspondent Name:</b>	MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO P.C.
<b>Address Line 1:</b>	ONE FINANCIAL CENTER
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02111
<b>ATTORNEY DOCKET NUMBER:</b>	048440-577C02US
<b>NAME OF SUBMITTER:</b>	EDWARD D. GRIEFF
<b>SIGNATURE:</b>	/Edward D. Grieff/
<b>DATE SIGNED:</b>	01/04/2019
<b>Total Attachments: 4</b>	
source=048440-577_Assignment-CIT#page1.tif	
source=048440-577_Assignment-CIT#page2.tif	
source=048440-577_Assignment-CIT#page3.tif	
source=048440-577_Assignment-CIT#page4.tif	

**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“DNA2 Inhibitors for Cancer Treatment,”

filed with the U.S. Patent & Trademark Office on February 8, 2016 and assigned serial no. 62/292,506; and on February 8, 2017 and assigned serial no. 15/428,021.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to California Institute of Technology, having a principal place of business at 1200 E. California Blvd., Pasadena, CA 91125 (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT


U.S. Serial Nos. 62/292,506 & 15/428,021

Attorney Docket Nos.: 48440-577P01US & 48440-577001US

Page 2 of 2

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph I of this Assignment.
  3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph I of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
  5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature:   
Judith Campbell

Date: 27 Nov 2017

Signature: \_\_\_\_\_  
Kenneth Karanja

Date: \_\_\_\_\_

Signed and hereby accepted on behalf of the Assignee:

Name

  
**Fred Farina**  
Chief Innovation & Corporate Partnerships Officer  
Office of Technology Transfer & Corporate Partnerships

12/13/17  
Date

73957956v.1

**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“DNA2 Inhibitors for Cancer Treatment,”

filed with the U.S. Patent & Trademark Office on February 8, 2016 and assigned serial no. 62/292,506; and on February 8, 2017 and assigned serial no. 15/428,021.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to California Institute of Technology, having a principal place of business at 1200 E. California Blvd., Pasadena, CA 91125 (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

U.S. Serial Nos. 62/292,506 & 15/428,021

Attorney Docket Nos.: 48440-577P01US & 48440-577001US

Page 2 of 2

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
  3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
  5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: \_\_\_\_\_

Judith Campbell

Date: \_\_\_\_\_

Signature:  \_\_\_\_\_

Kenneth Karanja

Date: 11/27/2017

Signed and hereby accepted on behalf of the Assignee:

 **Fred Farina** 12/13/17  
Name Chief Innovation & Corporate Partnerships Officer Date  
Office of Technology Transfer & Corporate Partnerships